Nkarta (NKTX) investor relations material

Organizational transformation and strategic focus

• Shifted from oncology to autoimmune disease, focusing on a single CD19 target across six indications, narrowing further based on data and enrollment trends.

• Transitioned team expertise from oncology to immunology, hiring rheumatologists and clinical staff with autoimmune experience.

• Streamlined manufacturing by reducing management layers, increasing efficiency, and extending cash runway.

• Cash runway extends into 2029, supporting multiple pivotal trials with a focus on cell therapy pivotal designs.

Clinical development and trial design

• Adopted full fludarabine/cyclophosphamide lymphodepletion for deeper B-cell depletion, aiming for durable remissions.

• Dose escalation ongoing, targeting up to 4 billion cells x 3 doses, with flexibility for redosing upon disease flare.

• Next clinical update will focus on best responses in key indications, with at least three months of follow-up.

• Decision on advancing indications will be based on efficacy, safety, enrollment pace, and competitive landscape.

Safety, efficacy, and regulatory engagement

• No cytokine release syndrome, neurotoxicity, or ICANS observed in autoimmune trials; safety profile seen as a key advantage.

• Building a safety database of ~100 patients, leveraging both autoimmune and oncology data for regulatory submissions.

• Consistent and efficient communication with FDA reviewers; regulatory environment seen as supportive of cell therapy.